On November 17, 2016, Chen Chuanhong, Director of Major Special Projects Office of the Ministry of Science and Technology and Secretary of the Party Branch, visited Beijing Orient Biotech Co., Ltd. and Biotech Pharmaceutical Co., Ltd. to investigate the latest progress of major innovative drug projects. Yang Zhe, Deputy Director of the Major Special Projects Office of the Ministry of Science and Technology, Xie Min, Inspector of the Major Special Projects Office of the Ministry of Science and Technology, Deputy Secretary of the Party Branch, Li Xiao, Director of the Comprehensive Coordination Office of the Major Special Projects Office of the Ministry of Science and Technology, Shen Yonggang, Deputy Director of the Management Committee, accompanied the investigation.

Chairman Bai Xianhong, General Manager Bai Yi and other senior executives of the company warmly welcomed Chen Chuanhong and his delegation. He held a symposium and accompanied the company to inspect the company's R&D platform and pilot plant.

At the symposium, Chairman Bai Xianhong, on behalf of Dongfang Baitai and Baitai Pharmaceutical, warmly welcomed the visit of Director Chen Chuanhong and his delegation. He reported to all leaders the latest progress of major special projects for innovative drugs of Dongfang Baitai and Baitai Pharmaceutical. It also introduces the company's growth history, drug R&D layout, status of listed drugs and future strategic planning.

After carefully listening to the report of the enterprise, Director Chen Chuanhong stressed that the enterprise should not only do its own production and research work well. At the same time, we should deepen the in-depth cooperation between innovative drugs and other platforms. The Major Office will also coordinate relevant departments in policy to ensure the implementation of the project. Ensure smooth green channel of key projects and fast approval.

Director Chen Chuanhong also pointed out that the enterprise should maintain the sustainability of drug innovation and make overall planning. In particular, the major new drug development projects under clinical research should be the primary goal. We should get the new drug certificate as soon as possible to realize the implementation of the achievements.

Enterprises should strengthen the publicity, promotion and application of innovative drugs that have been completed and received batch numbers. The company should make the transformation and application of innovative drugs produce better results and continue to benefit more patients. At the same time, the enterprise should be the leader of the industry, radiating and driving the sustainable and comprehensive development of upstream and downstream industries, and improving the overall level of the development of antibody drugs in China.

Later, Bai Yi, General Manager, led Director Chen Chuanhong and his delegation to inspect areas such as Dongfang Baitai innovative drug research and development platform and pilot plant to understand the process flow. During this period, Director Chen Chuanhong fully affirmed Dongfang Baitai's achievements in drug innovation, research and development and platform construction. He encouraged Dongfang Baitai to continue its efforts and make more contributions to overcoming the problem of human diseases and promoting people's health.

Bai Yi, the general manager of Dongfang Baitai, said that through continuous innovation, Dongfang Baitai will track the cutting-edge trends of biopharmaceuticals, strengthen technical research and development cooperation, strive to create new drugs with higher scientific and technological content and added value, and improve the company's market competitiveness and sustainable development ability. We will earnestly fulfill our social responsibilities, make every kind of medicine safe, reliable and reassuring, and strive to build Dongfang Baitai into a leading enterprise in the biomedical industry.